## Top 20 Causes of Mortality Throughout the World

### ALL COUNTRIES

<table>
<thead>
<tr>
<th>Rank</th>
<th>Cause</th>
<th>Total deaths (in thousands)</th>
<th>% of total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td><strong>ISCHAEMIC HEART DISEASE</strong></td>
<td>7,208</td>
<td>12.6</td>
</tr>
<tr>
<td>2.</td>
<td>CEREBROVASCULAR DISEASE</td>
<td>5,509</td>
<td>9.7</td>
</tr>
<tr>
<td>3.</td>
<td>LOWER RESPIRATORY INFECTIONS</td>
<td>3,884</td>
<td>6.8</td>
</tr>
<tr>
<td>4.</td>
<td>HIV/AIDS</td>
<td>2,777</td>
<td>4.9</td>
</tr>
<tr>
<td>5.</td>
<td>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</td>
<td>2,748</td>
<td>4.8</td>
</tr>
<tr>
<td>6.</td>
<td>DIARRHEAL DISEASES</td>
<td>1,798</td>
<td>3.2</td>
</tr>
<tr>
<td>7.</td>
<td>TUBERCULOSIS</td>
<td>1,566</td>
<td>2.7</td>
</tr>
<tr>
<td>8.</td>
<td>MALARIA</td>
<td>1,272</td>
<td>2.2</td>
</tr>
<tr>
<td>9.</td>
<td>CANCER OF TRACHEA/BRONCHUS/LUNG</td>
<td>1,243</td>
<td>2.2</td>
</tr>
<tr>
<td>10.</td>
<td>ROAD TRAFFIC ACCIDENTS</td>
<td>1,192</td>
<td>2.1</td>
</tr>
<tr>
<td>11.</td>
<td>CHILDHOOD DISEASES</td>
<td>1,124</td>
<td>2.0</td>
</tr>
<tr>
<td>12.</td>
<td>OTHER UNINTENTIONAL INJURIES</td>
<td>923</td>
<td>1.6</td>
</tr>
<tr>
<td>13.</td>
<td>HYPERTENSIIVE HEART DISEASE</td>
<td>911</td>
<td>1.6</td>
</tr>
<tr>
<td>14.</td>
<td>SELF-INFLICTED</td>
<td>873</td>
<td>1.5</td>
</tr>
<tr>
<td>15.</td>
<td>STOMACH CANCER</td>
<td>850</td>
<td>1.5</td>
</tr>
<tr>
<td>16.</td>
<td>CIRRHOSIS OF THE LIVER</td>
<td>786</td>
<td>1.4</td>
</tr>
<tr>
<td>17.</td>
<td>NEPHRITIS/NEPHROSIS</td>
<td>677</td>
<td>1.2</td>
</tr>
<tr>
<td>18.</td>
<td>COLON/RECTUM CANCER</td>
<td>622</td>
<td>1.1</td>
</tr>
<tr>
<td>19.</td>
<td>LIVER CANCER</td>
<td>618</td>
<td>1.1</td>
</tr>
<tr>
<td>20.</td>
<td>MEASLES</td>
<td>611</td>
<td>1.1</td>
</tr>
</tbody>
</table>

### Mortality: Ten Leading Causes (2001-2005)

**MORTALITY: TEN (10) LEADING CAUSES NUMBER AND RATE/100,000 POPULATION Philippines 5-Year Average (2001-2005) & 2006**

<table>
<thead>
<tr>
<th>CAUSES</th>
<th>5-Year Average (2001-2005)</th>
<th>2006*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Rate</td>
</tr>
<tr>
<td>1. Diseases of the Heart</td>
<td>69,741</td>
<td>85.5</td>
</tr>
<tr>
<td>2. Diseases of the Vascular System</td>
<td>52,106</td>
<td>64.0</td>
</tr>
<tr>
<td>3. Malignant Neoplasms</td>
<td>39,634</td>
<td>48.6</td>
</tr>
<tr>
<td>4. Accidents**</td>
<td>33,650</td>
<td>41.4</td>
</tr>
<tr>
<td>5. Pneumonia</td>
<td>33,764</td>
<td>41.5</td>
</tr>
<tr>
<td>6. Tuberculosis, all forms</td>
<td>27,017</td>
<td>33.2</td>
</tr>
<tr>
<td>7. Chronic lower respiratory diseases</td>
<td>19,024</td>
<td>23.3</td>
</tr>
<tr>
<td>8. Diabetes Mellitus</td>
<td>15,123</td>
<td>18.5</td>
</tr>
<tr>
<td>9. Certain conditions originating in the perinatal period</td>
<td>13,931</td>
<td>17.2</td>
</tr>
<tr>
<td>10. Nephritis, nephrotic syndrome and nephrosis</td>
<td>9,785</td>
<td>12.0</td>
</tr>
</tbody>
</table>

*Note: Excludes ill-defined and unknown causes of mortality

* *reference year

** External causes of Mortality
Audio video presentation of THROMBOSIS
AVAILABLE MEDICAL INTERVENTIONS

• Anticoagulants
• Antithrombotics
• Antiplatelets

COMMONLY KNOWN:

• Aspirin
• Warfarin
• Clopidogrel
• Dypiridamole

The Bitter Truth….
ALL DRUGS HAVE INEVITABLE SIDE EFFECTS
SIDE EFFECTS

• BLEEDING
• Blood dyscrasia/disorders
• Drug Interactions
• Hypersensitivity Reaction
• GIT Irritation
Has led to man’s continuous
QUEST FOR NATURAL
WAYS TO PREVENT
DISEASE....

NattoShield

Heart Protection with Nattokinase
300 mg per Softgel
- Natural Anticoagulant
- Blood Flow Normalizer
- Nattokinase enzyme for improved circulation

STORAGE
Keep out of reach of children.
Avoid direct exposure to sunlight.
Store in a cool dry place.
Keep plastic lighter closed after use.

RECOMMENDATION
Take one softgel daily with a glass of water before or after meals as directed by a physician.

Dietary Supplement

NO APPROVED THERAPEUTIC CLAIMS

LOT 36573

VITAL C
Health Products, Inc.
NATTOKINASE

• *Nattokinase* (NattoShield) is an all natural dietary supplement, used in the prevention of cardiac and cerebrovascular diseases.

produced from non-genetically modified soybeans and a selected, patented strain of *Bacillus subtilis natto*.

gawa sa natural at purong soybeans

has fibrinolytic and thrombolytic properties

tulong sa pagtunaw ng namuong dugo

does not inhibiting blood clot formation which is part of the body’s self-preserving mechanisms during injury.

napapanatili ang kakayahan ng katawan na gumawa ng blood clots kapag nasugatan
Development Background

NKCP®

Purified Filtrate of *Bacillus subtilis* natto Culture
People's Health Promotion Campaign for the 21st Century (Healthy Japan 21)” was launched in 2000 by the Ministry of Health, Labour and Welfare

- Purposes of campaign:
  - To reduce premature death, prolong optimal health, improve the quality of life
    - Maiwasan ang maagang kamatayan, humaba ang buhay at magkaroon ng buhay na matiwasay
  - Focuses on *longevity accompanied by optimal health.*
    - Nakatuon sa pagpapahaba ng buhay na matiwasay
Mode of Action

• Purified *Nattokinase* (*NattoShield*) has been shown to degrade fibrin clots both directly and indirectly.

  Pantunaw ng blood clot

• Helps reduce elevated blood pressure in human volunteers with hypertension.

  Tulong sa mga may high blood

• Can inhibit platelet aggregation

  Pagpigil sa pagdidikit ng platelets

• Helps reduce rouleaux formation in red blood cells

  Pagpigil sa pagdidikit dikit ng red blood cells.

• Helps decrease blood viscosity, thereby enhancing circulation.

  Pagpigil sa paglapot ng dugo
Benefits

- **Anticoagulant Effect**
  Pampigil sa paglapot ng dugo

- **Thrombolytic Effect**
  Pantunaw ng namuong dugo

- **Antithrombotic Effect**
  Pampigil sa pamumuo ng blood clot

- **Reduces Rouleaux Formation**
  Pampigil sa padidikit dikit ng red blood cells

- **Helps to lower blood pressure**
  Pantulong sa pagkakaroon ng normal BP

- **Oral Bioavailability**
  Maaring inumin, di kailangang iturok
References

NSK-SD Nattokinase
A Comprehensive Scientific Review of Nattokinase
By Japan Bio Science Laboratories Company Limited

Effect of Bacillus subtilis natto culture (NKCP) on coagulation and fibrinolysis"
IFF 2007 (International Society of Food Function), Tokyo, Japan
Hitosugi M. (Department of Legal Medicine, Dokkyo University School of Medicine), Kato H., Zhu X., Yanagisawa H. (Daiwa Pharmaceutical Co., Ltd.), and Tokudome S. (Institute for Medical Science, Dokkyo Medical University School of Medicine)

"Anticoagulant and fibrinolytic effects of functional food materials produced by Bacillus subtilis natto"
The 54th Society of Rheology, Fukuoka, Japan
Hitosugi M., Omura K., and Tokudome S. (Department of Legal Medicine, Dokkyo University School of Medicine), Ikeda M. (Institute for Medical Science, Dokkyo Medical University School of Medicine), Kato H., Zhu X. (Daiwa Pharmaceutical Co., Ltd.)

Rheology of Thrombosis and Thrombolysis
M. Hitosugi (Department of Legal Medicine, Dokkyo University School of Medicine)

"A possibility of the influence upon human blood rheology by the competently refined protein layer from cultured Bacillus subtilis natto."
International Congress on Rheology 2004, Korea
Omura K., Hitosugi M. (Dokkyo University School of Medicine, Department of Legal Medicine), X. Zhu (Daiwa Pharmaceutical Co., Ltd.) et al.

"The protein layer of Bacillus subtilis natto cultured medium changes the activity of both blood coagulation and fibrinolysis."
21st Symposium of Medical and Pharmaceutical Society for WAKAN-YAKU, Toyama
Omura K., Hitosugi M. (Dokkyo University School of Medicine, Department of Legal Medicine), Kudo M., X. Zhu (Daiwa Pharmaceutical Co., Ltd.), Ikeda M. (Dokkyo University School of Medicine), S. Tokutome (Dokkyo University School of Medicine, Department of Legal Medicine) et al.

2004 Symposium of AOAC International Japan Section, Tokyo
Xia Z. (Daiwa Pharmaceutical Co., Ltd.), Omura K. (Dokkyo University School of Medicine, Department of Legal Medicine), Hashimoto M. (Shima Research Co., Ltd.) et al.

27th Meeting of Japanese Society of Biorehology
Hitosugi M., Omura K. (Dokkyo University School of Medicine, Department of Legal Medicine), Niwa M. (Chiba University of Commerce, Department of Policy Informatics) and S. Tokutome (Dokkyo University School of Medicine, Department of Legal Medicine)

The 3rd International Conference on Food Factors: Physiologic Functions and Disease Risk Reduction,
K. Omura (Dokkyo University School of Medicine, Department of Legal Medicine)

5th Meeting of 21st Century Food and Health Forum, Tokyo
Omura K., Hitosugi M. (Dokkyo University School of Medicine, Department of Legal Medicine), Kaketani K. (Hanzomon Gastrointestinal Clinic), X. Zhu (Daiwa Pharmaceutical Co., Ltd.) et al.
References

51st Discussion of Rheology, Nara
Omura K., Hitosugi M., Tokutome S., Nagai T. (Dokkyo University School of Medicine, Department of Legal Medicine), Ikeda M. (Dokkyo University School of Medicine), X. Zhu (Daiwa Pharmaceutical Co., Ltd.) and M. Niwa (Chiba University of Commerce, Department of Policy Informatics)

26th Meeting of the Japanese Society of Biorheology
Omura K., Hitosugi M., Tokutome S. (Dokkyo University School of Medicine, Department of Legal Medicine), Niwa M. (Chiba University of Commerce, Department of Policy Informatics), Koike Y. (The Jikei University), Yufu T. and N. Iida (The Jikei University)


